BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 8967982)

  • 21. Differentiation induces pituitary adenylate cyclase-activating polypeptide receptor expression in PC-12 cells.
    Cavallaro S; D'Agata V; Guardabasso V; Travali S; Stivala F; Canonico PL
    Mol Pharmacol; 1995 Jul; 48(1):56-62. PubMed ID: 7623775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
    Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
    Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Receptors for pituitary adenylate cyclase-activating peptide in human liver.
    Guijarro LG; Rodriguez-Henche N; García-López E; Noguerales F; Dapena MA; Juarranz MG; Prieto JC
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2451-7. PubMed ID: 7629241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; Rathé J; De Neef P; Robberecht P
    Regul Pept; 1996 Apr; 62(2-3):125-30. PubMed ID: 8795075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23.
    Vertongen P; Ciccarelli E; Woussen-Colle MC; De Neef P; Robberecht P; Cauvin A
    Endocrinology; 1994 Oct; 135(4):1537-42. PubMed ID: 7925114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
    Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
    Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; Rathé J; De Neef P; Robberecht P
    Eur J Pharmacol; 1995 Dec; 287(1):7-11. PubMed ID: 8666028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines.
    Waschek JA; Lelievre V; Bravo DT; Nguyen T; Muller JM
    Peptides; 1997; 18(6):835-41. PubMed ID: 9285932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
    Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
    Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase activating polypeptide (PACAP).
    Hosoya M; Onda H; Ogi K; Masuda Y; Miyamoto Y; Ohtaki T; Okazaki H; Arimura A; Fujino M
    Biochem Biophys Res Commun; 1993 Jul; 194(1):133-43. PubMed ID: 7687425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Waelbroeck M; Robberecht P
    Biochim Biophys Acta; 1996 Dec; 1314(3):267-73. PubMed ID: 8982281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
    Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
    J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of VIP1/PACAP receptors in postoperative ileus in rats.
    De Winter BY; Robberecht P; Boeckxstaens GE; De Man JG; Moreels TG; Herman AG; Pelckmans PA
    Br J Pharmacol; 1998 Jul; 124(6):1181-6. PubMed ID: 9720789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves.
    Fahrenkrug J; Hannibal J; Tams J; Georg B
    J Cereb Blood Flow Metab; 2000 Aug; 20(8):1205-14. PubMed ID: 10950381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
    Zawilska JB; Niewiadomski P; Nowak JZ
    J Mol Neurosci; 2003 Apr; 20(2):153-62. PubMed ID: 12794309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas.
    Vertongen P; Devalck C; Sariban E; De Laet MH; Martelli H; Paraf F; Hélardot P; Robberecht P
    J Cell Physiol; 1996 Apr; 167(1):36-46. PubMed ID: 8698838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
    Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
    Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
    Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.